Abstract
Chronic inflammation and oxidative stress are common and co-substantial pathological processes accompanying and contributing to cancers. Numerous epidemiological studies have indicated that non-steroidal anti-inflammatory drugs (NSAIDs) could have a positive effect on both the prevention of cancer and tumor therapy. Numerous hypotheses have postulated that NSAIDs could slow tumor growth by acting on both chronic inflammation and oxidative stress. This review takes a closer look at these hypotheses. In the cancer process, one of the major signaling pathways involved is the WNT/β-catenin pathway, which appears to be upregulated. This pathway is closely associated with both chronic inflammation and oxidative stress in cancers. The administration of NSAIDs has been observed to help in the downregulation of the WNT/β-catenin pathway and thus in the control of tumor growth. NSAIDs act as PPARγ agonists. The WNT/β-catenin pathway and PPARγ act in opposing manners. PPARγ agonists can promote cell cycle arrest, cell differentiation, and apoptosis, and can reduce inflammation, oxidative stress, proliferation, invasion, and cell migration. In parallel, the dysregulation of circadian rhythms (CRs) contributes to cancer development through the upregulation of the canonical WNT/β-catenin pathway. By stimulating PPARγ expression, NSAIDs can control CRs through the regulation of many key circadian genes. The administration of NSAIDs in cancer treatment would thus appear to be an interesting therapeutic strategy, which acts through their role in regulating WNT/β-catenin pathway and PPARγ activity levels.
Highlights
The complex process of cancer can be defined in terms of three stages: initiation, promotion, and progression [1,2,3]
This review focuses on the interest of using non-steroidal anti-inflammatory drugs (NSAIDs) in cancer therapy through their capacity to regulate the aberrant canonical WNT/β-catenin pathway and peroxisome proliferator receptor γ (PPARγ), two systems that respond in an opposite manner
The WNT/β-catenin pathway is generally activated whereas PPARγ is decreased
Summary
The complex process of cancer can be defined in terms of three stages: initiation, promotion, and progression [1,2,3]. An aberrant WNT/β-catenin pathway is generally observed and leads to oxidative stress and inflammation [12,17,18]. Many studies have shown that inflammatory factors, including interleukins, TNF-α, nuclear factor-κB (NF-κB) and ROS production-induced inflammation, infiltrate the inflammatory microenvironment, leading to DNA damage and the initiation of the cancer process [25,26]. The disruption of circadian rhythms (CRs) has been shown in cancers [29] This dysregulation upregulates the canonical WNT/β-catenin pathway, which participates in the cancer process. This review focuses on the interest of using NSAIDs in cancer therapy through their capacity to regulate the aberrant canonical WNT/β-catenin pathway and PPARγ, two systems that respond in an opposite manner
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
